NCT05151692View on ClinicalTrials.gov

A Study of JNJ-80202135 in Healthy Chinese Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

September 9, 2022

Study Completion Date

September 9, 2022

Conditions

Healthy

Interventions

DRUG

Nipocalimab

Nipocalimab will be administered as an IV infusion.

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY